CD68 Antibody Clone: GR021 Ready-To-Use
- Known as:
- CD68 Antibody Clone: GR021 Ready-To-Use
- Catalog number:
- 60-0184-7
- Product Quantity:
- 7mL
- Category:
- -
- Supplier:
- Genemed
- Gene target:
- CD68 Antibody Clone: GR021 Ready-To-Use
Related genes to: CD68 Antibody Clone: GR021 Ready-To-Use
- Gene:
- CD68 NIH gene
- Name:
- CD68 molecule
- Previous symbol:
- -
- Synonyms:
- SCARD1, macrosialin, GP110, DKFZp686M18236, LAMP4
- Chromosome:
- 17p13.1
- Locus Type:
- gene with protein product
- Date approved:
- 1993-06-11
- Date modifiied:
- 2016-10-05
Related products to: CD68 Antibody Clone: GR021 Ready-To-Use
Related articles to: CD68 Antibody Clone: GR021 Ready-To-Use
- Oral squamous cell carcinoma (OSCC) is one of the most prevalent cancers in India. Significant research over the last 10 years has revealed that the inflammatory tumour microenvironment is crucial to the development of OSCC. Macrophages account for 30-50% with subtypes M1 and M2, hence called as tumour-associated macrophages (TAMs). It was a laboratory-based observational study conducted on 88 histologically proven cases of OSCC to determine the immunohistochemical expression of TAMs and to find its association with lymph node metastasis and TNM staging. Screening for lymph node metastasis, grading and TNM staging were done according to the new AJCC staging criteria followed by immunohistochemical staining of the same using CD68 and CD163. The mean age observed was 48.5 years with a female preponderance. Strong cytoplasmic positivity for CD68 was noted in 21.5% of cases whereas strong membranous positivity for CD163 was noted in 70% of cases. 43.18% of cases had nodal involvement. 5.6%, 17%, 34% and 43.4% of cases belonged to TNM stages I, II, III and IV respectively. CD68 positivity score was higher in node negative cases. Increased CD163 TAMs score was linked to lymph node positivity ( = 0.003) and higher TNM stages ( = 0.014). When assessing OSCC, the important role of the tumour microenvironment must be taken into account. TAMs show promise as a marker for tumour aggressiveness and as possible targets for immunotherapy. - Source: PubMed
Publication date: 2025/08/05
Khumanthem SharjubalaSuresh T NKattepur Abhay K - Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm, most commonly occurring in children and young adults. It is typically locally aggressive and rarely metastasizes. Adult-onset IMTs with extensive metastasis are exceedingly uncommon, particularly with large pulmonary involvement, and can mimic sarcoma or sarcomatoid carcinoma on imaging and histology. Anaplastic lymphoma kinase () positivity aids diagnosis and provides a potential therapeutic target. A 56-year-old male presented with progressively worsening dyspnea, nonproductive cough, and right-sided chest pain. Computed tomography revealed a 9-cm right hilar and upper lobe mass causing complete obstruction of the right upper lobe bronchus, with extensive mediastinal lymphadenopathy. Bronchoscopic biopsy demonstrated a malignant spindle cell neoplasm with sarcomatoid and myxoid features. Immunohistochemistry was positive for , CD68, and vimentin, and negative for epithelial, smooth muscle, neural, and melanocytic markers (AE1/3, p40, TTF-1, CK7, CK20, CDX2, SMA, desmin, SOX10, S100, and calretinin). Staging imaging revealed a mesenteric mass adjacent to the ascending colon. Biopsy of the colonic lesion showed morphologically and immunohistochemically similar features, supporting a diagnosis of metastatic IMT confirmed by multidisciplinary pathology review. The patient's clinical course was rapidly progressive, and he died two months after initial presentation. Adult-onset -positive IMT with extensive pulmonary involvement and multiorgan metastases is exceedingly rare. This case highlights the diagnostic challenges posed by sarcomatoid morphology and underscores the importance of integrating histopathology, immunohistochemistry, and clinical correlation, with testing providing both diagnostic confirmation and a potential therapeutic target. - Source: PubMed
Publication date: 2026/04/26
Rahman ZehraScotto TiffanyDen Boef AlexanderGaudin JulieElmanaseer Oday - Juvenile xanthogranuloma (XGJ) is a generally benign non-Langerhans cell histiocytosis (non-LCH) that primarily affects infants and children. It typically presents as a single skin lesion. Disseminated and profuse forms remain rare and can pose diagnostic or therapeutic challenges. The classification of histiocytoses has recently evolved, incorporating disseminated XGJ into group "C" of non-LCH cutaneous histiocytoses. While the prognosis for isolated cutaneous forms is excellent, vigilance regarding potential associations (type 1 neurofibromatosis and juvenile myelomonocytic leukemia) and systemic complications remains essential. We report the case of a four-month-old infant presenting with a purely cutaneous disseminated form of XGJ, confirmed by histopathology and immunohistochemistry, which required systemic corticosteroid therapy due to the rapid spread of the lesions. This study involves a four-month-old infant with no significant family history who has been presenting with gradually progressive papular skin lesions for one month. Clinical examination revealed multiple umbilicated, yellowish-brown papulonodules scattered across the face, trunk, limbs, skin folds, genital mucosa, and scalp; a café-au-lait spot was detected on one limb. Dermoscopy revealed a characteristic "sunset" pattern. Histopathological and immunohistochemical analysis (CD68+, CD163+, CD1a-, CD34-, S100-) confirmed the diagnosis. The staging evaluation revealed no abnormalities. After three months of simple monitoring, the extensive spread of the lesions prompted the initiation of oral corticosteroid therapy (1 mg/kg/day), resulting in partial regression at six weeks. Disseminated XGJ in infants remains a rare condition. Although the course is most often self-limiting, justifying an initial conservative approach, certain extensive forms may require systemic treatment. The dermatologist plays a central role in diagnosis, based on a combination of clinical, dermoscopic, histopathological, and immunohistochemical findings, and in the multidisciplinary decision-making regarding treatment. - Source: PubMed
Publication date: 2026/04/30
Okouango Emelie SimoneBaghad BouchraRachadi HananeChiheb Soumiya - Granular cell tumor (GCT) is a neoplasm of uncertain histopathological origin; therefore, no uniformly accepted treatment strategy has yet been established. Microscopically, it is characterized by eosinophilic granules. This tumor involves the skin and subcutaneous tissue. Gastrointestinal involvement is uncommon; however, isolated granular cell tumors of the esophagus, stomach, and colon, as well as multifocal lesions of the esophagus and stomach, have been reported. Diffuse involvement of the entire gastrointestinal tract has not been described. We report the case of a 20-year-old woman who presented with a chronic cough. Chest computed tomography revealed a retrotracheal mass, which was surgically resected and ultimately diagnosed as a GCT. Upper gastrointestinal endoscopy, performed to investigate dyspepsia, revealed multiple synchronous GCTs throughout the esophagus, stomach, and duodenum. Endoscopic ultrasound of the largest identified nodule revealed a well-defined hypoechoic lesion confined to the second hypoechoic layer; all remaining lesions demonstrated similar ultrasonographic features. This lesion was resected "in bloc" without adverse events using endoscopic mucosal resection for diagnostic and therapeutic purposes. Immunohistochemical (IHC) analysis demonstrated positivity for S100 and CD68, with expression of CD34 also observed. The patient has been followed on an outpatient basis, and symptoms of postprandial fullness and abdominal discomfort have been managed conservatively, with satisfactory symptomatic relief to date. Immunohistochemistry was sufficient for the definitive classification of the lesion as a GCT, and endoscopic mucosal resection appears to be an appropriate diagnostic approach for lesions larger than 20 mm. Furthermore, the authors discuss the optimal surveillance strategy for patients with disseminated GCTs of the gastrointestinal tract. - Source: PubMed
Publication date: 2026/04/28
Kodra LaraLage Amanda AWanderley MarcellaPinheiro Carolina Tde Oliveira Pedro BBarroso Fernanda CVenco Filadélfio EArdengh Jose CZuccaro Ana M - Neoadjuvant immunochemotherapy (nICT) has emerged as a promising strategy for locally advanced gastric cancer (LAGC), yet clinical responses remain heterogeneous and reliable predictive biomarkers are lacking. A comprehensive dissection of the tumor microenvironment (TME) is essential to uncover determinants of therapeutic efficacy and enable precision immunotherapy. - Source: PubMed
Publication date: 2026/05/14
Xu XiaohongFan JunPeng LiXiang ZhengkaiLuo DanjuMa ChenggongHuang BoNie XiuDong Xiaochuan